Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.

@article{Pfaller2008SelectionOA,
  title={Selection of a surrogate agent (fluconazole or voriconazole) for initial susceptibility testing of posaconazole against Candida spp.: results from a global antifungal surveillance program.},
  author={Michael A. Pfaller and Shawn A. Messer and Linda B Boyken and Shailesh Tendolkar and Richard J. Hollis and Daniel J. Diekema},
  journal={Journal of clinical microbiology},
  year={2008},
  volume={46 2},
  pages={551-9}
}
There are currently no FDA-approved broth microdilution antifungal susceptibility testing products or interpretive breakpoints for susceptibility testing of the new triazole posaconazole. Fluconazole and voriconazole are in the same triazole class as posaconazole, have CLSI-approved interpretive MIC breakpoints, and are available on some commercially available MIC panels. We investigated whether one or both of these agents may be useful as a surrogate marker for posaconazole susceptibility… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-10 of 33 extracted citations

Efflux-mediated antifungal drug resistance.

Clinical microbiology reviews • 2009
View 6 Excerpts
Highly Influenced

Similar Papers

Loading similar papers…